Peptron Inc Net Assets
Peptron Inc net assets. Based on the latest financial reports, Peptron Inc (087010) has net assets worth ₩129.48 Billion KRW (≈ $87.74 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩167.98 Billion ≈ $113.83 Million USD) and total liabilities (₩38.50 Billion ≈ $26.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 087010 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩129.48 Billion |
| % of Total Assets | 77.08% |
| Annual Growth Rate | 31.17% |
| 5-Year Change | 128.01% |
| 10-Year Change | 166.89% |
| Growth Volatility | 117.73 |
Net Assets of Peptron Inc (2014–2025)
Net assets of Peptron Inc from 2014 to 2025. This chart illustrates how Peptron Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Peptron Inc to measure how much of total assets are equity-financed.
Annual Net Assets for Peptron Inc (2014–2025)
The table below shows the annual net assets of Peptron Inc from 2014 to 2025. For live market cap and overall valuation, see Peptron Inc (087010) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩142.01 Billion ≈ $96.24 Million |
-6.39% |
| 2024-12-31 | ₩151.71 Billion ≈ $102.81 Million |
+319.93% |
| 2023-12-31 | ₩36.13 Billion ≈ $24.48 Million |
-31.98% |
| 2022-12-31 | ₩53.11 Billion ≈ $35.99 Million |
-14.73% |
| 2021-12-31 | ₩62.28 Billion ≈ $42.21 Million |
-19.25% |
| 2020-12-31 | ₩77.13 Billion ≈ $52.27 Million |
+174.63% |
| 2019-12-31 | ₩28.09 Billion ≈ $19.03 Million |
-37.72% |
| 2018-12-31 | ₩45.10 Billion ≈ $30.56 Million |
-7.86% |
| 2017-12-31 | ₩48.95 Billion ≈ $33.17 Million |
-8.01% |
| 2016-12-31 | ₩53.21 Billion ≈ $36.06 Million |
+208.86% |
| 2015-12-31 | ₩17.23 Billion ≈ $11.67 Million |
+139.90% |
| 2014-12-31 | ₩7.18 Billion ≈ $4.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Peptron Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12232162634000.0% over the analyzed period, indicating profitable operations and earnings retention.
Peptron Inc Net Assets Breakdown (December 2025)
Peptron Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩106.06 Billion | 74.69% |
| Other Components | ₩35.94 Billion | 25.31% |
| Total Equity | ₩142.01 Billion | 100.00% |
Peptron Inc Competitors by Market Cap
The table below lists competitors of Peptron Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Econergy Renewable Energy Ltd
TA:ECNR
|
$958.89 Million |
|
PNC Process Systems Co Ltd
SHG:603690
|
$959.96 Million |
|
KPC Pharmaceuticals Inc
SHG:600422
|
$960.37 Million |
|
MAP Aktif Adiperkasa Tbk PT
JK:MAPA
|
$960.38 Million |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
$957.78 Million |
|
Oric Pharmaceuticals Inc
NASDAQ:ORIC
|
$957.75 Million |
|
Life Healthcare
JSE:LHC
|
$957.49 Million |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
$957.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Peptron Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 151,708,566,270 to 142,008,659,500, a change of -9,699,906,770 (-6.4%).
- Net loss of 13,823,782,610 reduced equity.
- New share issuances of 361,507,670 increased equity.
- Other factors increased equity by 3,762,368,170.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-13.82 Billion | -9.73% |
| Share Issuances | ₩361.51 Million | +0.25% |
| Other Changes | ₩3.76 Billion | +2.65% |
| Total Change | ₩- | -6.39% |
Book Value vs Market Value Analysis
This analysis compares Peptron Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.81x to 15.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4045.86 | ₩92300.00 | x |
| 2017-12-31 | ₩3137.08 | ₩92300.00 | x |
| 2018-12-31 | ₩2798.09 | ₩92300.00 | x |
| 2019-12-31 | ₩1742.57 | ₩92300.00 | x |
| 2020-12-31 | ₩3739.46 | ₩92300.00 | x |
| 2021-12-31 | ₩3019.50 | ₩92300.00 | x |
| 2022-12-31 | ₩2574.77 | ₩92300.00 | x |
| 2023-12-31 | ₩1757.76 | ₩92300.00 | x |
| 2024-12-31 | ₩6532.58 | ₩92300.00 | x |
| 2025-12-31 | ₩6109.64 | ₩92300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Peptron Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -245.33%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.26x
- Recent ROE (-9.73%) is above the historical average (-24.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -47.03% | -122.66% | 0.21x | 1.79x | ₩-3.69 Billion |
| 2015 | -15.85% | -97.09% | 0.13x | 1.26x | ₩-4.45 Billion |
| 2016 | -6.00% | -101.93% | 0.05x | 1.09x | ₩-8.51 Billion |
| 2017 | -9.04% | -137.68% | 0.06x | 1.08x | ₩-9.32 Billion |
| 2018 | -8.26% | -96.48% | 0.05x | 1.59x | ₩-8.24 Billion |
| 2019 | -63.08% | -983.70% | 0.03x | 2.17x | ₩-20.53 Billion |
| 2020 | -23.83% | -589.03% | 0.03x | 1.53x | ₩-26.10 Billion |
| 2021 | -24.15% | -227.07% | 0.09x | 1.25x | ₩-21.27 Billion |
| 2022 | -28.36% | -259.08% | 0.09x | 1.29x | ₩-20.37 Billion |
| 2023 | -44.07% | -476.43% | 0.06x | 1.45x | ₩-19.53 Billion |
| 2024 | -14.52% | -699.00% | 0.02x | 1.11x | ₩-37.20 Billion |
| 2025 | -9.73% | -245.33% | 0.03x | 1.26x | ₩-28.02 Billion |
Industry Comparison
This section compares Peptron Inc's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $105,566,909,213
- Average return on equity (ROE) among peers: -10.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Peptron Inc (087010) | ₩129.48 Billion | -47.03% | 0.30x | $958.68 Million |
| Macrogen Inc (038290) | $177.43 Billion | -4.29% | 0.86x | $74.03 Million |
| Panagene Inc (046210) | $16.66 Billion | -24.25% | 1.30x | $27.42 Million |
| Cell Biotech Co. Ltd (049960) | $124.17 Billion | 12.18% | 0.05x | $77.43 Million |
| Bioneer Corporation (064550) | $30.61 Billion | -25.57% | 1.68x | $101.98 Million |
| MEDIPOST Co. Ltd (078160) | $252.60 Billion | -24.75% | 0.64x | $84.32 Million |
| Biotoxtech Co. Ltd (086040) | $31.93 Billion | 3.64% | 3.12x | $19.72 Million |
About Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more